45,042 Shares in Nektar Therapeutics $NKTR Bought by Readystate Asset Management LP

Readystate Asset Management LP bought a new position in shares of Nektar Therapeutics (NASDAQ:NKTR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 45,042 shares of the biopharmaceutical company’s stock, valued at approximately $2,563,000. Readystate Asset Management LP owned about 0.24% of Nektar Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in NKTR. FNY Investment Advisers LLC purchased a new stake in shares of Nektar Therapeutics in the 2nd quarter valued at about $39,000. Headlands Technologies LLC acquired a new position in Nektar Therapeutics during the second quarter worth approximately $65,000. Integrated Wealth Concepts LLC purchased a new stake in Nektar Therapeutics in the first quarter valued at approximately $68,000. Compass Wealth Management LLC acquired a new stake in shares of Nektar Therapeutics in the third quarter valued at approximately $88,000. Finally, Bessemer Group Inc. grew its position in shares of Nektar Therapeutics by 1,741.2% during the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 1,480 shares during the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Trading Up 3.5%

NKTR stock opened at $73.82 on Wednesday. The firm’s 50-day moving average is $44.66 and its two-hundred day moving average is $47.65. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -9.26 and a beta of 1.34. Nektar Therapeutics has a 52 week low of $6.45 and a 52 week high of $74.89.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on NKTR shares. Jefferies Financial Group reissued a “buy” rating on shares of Nektar Therapeutics in a research note on Wednesday, December 17th. William Blair raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 10th. Piper Sandler reiterated an “overweight” rating and issued a $105.00 price target on shares of Nektar Therapeutics in a research report on Monday, January 26th. BTIG Research lifted their price objective on Nektar Therapeutics from $118.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Nektar Therapeutics in a research note on Monday, December 29th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $119.86.

Insiders Place Their Bets

In other Nektar Therapeutics news, insider Mark Andrew Wilson sold 630 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total value of $34,196.40. Following the completion of the transaction, the insider owned 21,585 shares of the company’s stock, valued at $1,171,633.80. This represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jonathan Zalevsky sold 3,867 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the sale, the insider directly owned 21,354 shares in the company, valued at $761,697.18. This trade represents a 15.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 7,861 shares of company stock valued at $354,730 over the last quarter. Insiders own 3.71% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.